Overall, our study elucidated the distinct treatment landscape for VP-MCC and VN-MCC, led to the discovery of AURKB as a novel MCC therapeutic target, and identified a nanoparticle-based AURKB inhibitor as a new potential treatment for MCC. The gene discussed is AURKB; the disease is Merkel cell skin cancer.